Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans.

The onset, intensity and duration of therapeutic response to a compound depend on the intrinsic pharmacological activity of the drug and pharmacokinetic factors related to its absorption, distribution, metabolism and elimination that are inherent to the biological system. The process of drug transfer from the site of administration to the systemic circulation and the interspecies factors that impact this process are the scope of this review. In general, the factors that influence oral drug bioavailability via absorption and metabolism can be divided into physicochemical/biopharmaceutical and physiological factors. Physicochemical and biopharmaceutical factors that influence permeability and solubility tend to be species independent. Although there are significant differences in the anatomy and physiology of the gastrointestinal tract, these are not associated with significant differences in the rate and extent of drug absorption between rats and humans. However, species differences in drug metabolism in rats and humans did result in significant species differences in bioavailability. Overall, this review provides a better understanding of the interplay between drug physicochemical/biopharmaceutical factors and species differences/similarities in the absorption and metabolism mechanisms that affect oral bioavailability in rats and humans. This will enable a more rational approach to perform projection of oral bioavailability in human using available rat in vivo data.

[1]  T. Kararli Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals , 1995, Biopharmaceutics & drug disposition.

[2]  Leslie Z. Benet,et al.  Effects of Ketoconazole on Digoxin Absorption and Disposition in Rat , 1998, Pharmacology.

[3]  M. Shimada,et al.  Isolation and Characterization of a New Major Intestinal CYP3A Form, CYP3A62, in the Rat , 2004, Journal of Pharmacology and Experimental Therapeutics.

[4]  O. Pelkonen,et al.  The functional role of CYP2B6 in human drug metabolism: substrates and inhibitors in vitro, in vivo and in silico. , 2006, Current drug metabolism.

[5]  J. Goldstein,et al.  Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. , 2001, British journal of clinical pharmacology.

[6]  Mary F Paine,et al.  THE HUMAN INTESTINAL CYTOCHROME P450 “PIE” , 2006, Drug Metabolism and Disposition.

[7]  Younggil Kwon,et al.  Handbook of Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism for Industrial Scientists , 2001, Springer US.

[8]  F. Gonzalez,et al.  The molecular biology of cytochrome P450s. , 1988, Pharmacological reviews.

[9]  I R Rowland,et al.  In vivo and in vitro models of the human colonic flora. , 1992, Critical reviews in food science and nutrition.

[10]  Barry C. Jones,et al.  DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS , 2004, Drug Metabolism and Disposition.

[11]  E. Warner,et al.  Patient preferences for oral versus intravenous palliative chemotherapy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  W. L. Chiou New perspectives on the theory of permeability and resistance in the study of drug transport and absorption , 1996, Journal of Pharmacokinetics and Biopharmaceutics.

[13]  C. Nyström,et al.  Dissolution rate measurements of sparingly soluble compounds with the Coulter Counter model TAII § , 1985, The Journal of pharmacy and pharmacology.

[14]  L. Goodman,et al.  The Pharmacological Basis of Therapeutics , 1941 .

[15]  A. Li,et al.  Species comparison in P450 induction: effects of dexamethasone, omeprazole, and rifampin on P450 isoforms 1A and 3A in primary cultured hepatocytes from man, Sprague-Dawley rat, minipig, and beagle dog. , 2001, Chemico-biological interactions.

[16]  C. Porter,et al.  The Lymph Lipid Precursor Pool Is a Key Determinant of Intestinal Lymphatic Drug Transport , 2006, Journal of Pharmacology and Experimental Therapeutics.

[17]  M. Otsuka,et al.  Pharmaceutical Evaluation of Carbamazepine Modifications: Comparative Study for Photostability of Carbamazepine Polymorphs by using Fourier‐transformed Reflection‐absorption Infrared Spectroscopy and Colorimetric Measurement , 1994, The Journal of pharmacy and pharmacology.

[18]  M. Másson,et al.  Cyclodextrins and drug permeability through semi-permeable cellophane membranes. , 2002, International journal of pharmaceutics.

[19]  S. Wrighton,et al.  Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). , 1990, Molecular pharmacology.

[20]  Michael B. Bolger,et al.  The composite solubility versus pH profile and its role in intestinal absorption prediction , 2008, AAPS PharmSci.

[21]  K. Beaumont,et al.  Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist. , 2003, Current drug metabolism.

[22]  Ulrich M. Zanger,et al.  Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry , 2003, Naunyn-Schmiedeberg's Archives of Pharmacology.

[23]  A. Barve,et al.  Linear Correlation of the Fraction of Oral Dose Absorbed of 64 Drugs Between Humans and Rats , 1998, Pharmaceutical Research.

[24]  W. Hayton Rate-limiting barriers to intestinal drug absorption: A review , 1980, Journal of Pharmacokinetics and Biopharmaceutics.

[25]  M. Fromm,et al.  Differential expression and function of CYP2C isoforms in human intestine and liver. , 2003, Pharmacogenetics.

[26]  H. Yamazaki,et al.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.

[27]  M. Healy,et al.  THEORETICAL MODEL OF GASTROINTESTINAL ABSORPTION OF LEAD , 1984, Journal of clinical and hospital pharmacy.

[28]  Denis M. Bayada,et al.  Polar Molecular Surface as a Dominating Determinant for Oral Absorption and Brain Penetration of Drugs , 1999, Pharmaceutical Research.

[29]  Han van de Waterbeemd,et al.  Pharmacokinetics and metabolism in drug design , 2001 .

[30]  D. Scott,et al.  Pharmacokinetics of lidocaine in man , 1971, Clinical pharmacology and therapeutics.

[31]  Chaumeil Jc Micronization: a method of improving the bioavailability of poorly soluble drugs. , 1998 .

[32]  G. L. Kedderis,et al.  Sex-dependent metabolism of xenobiotics. , 1998, Drug metabolism reviews.

[33]  B. Chauhan,et al.  Cyclodextrins: application in different routes of drug administration. , 2005, Acta pharmaceutica.

[34]  R. Edwards,et al.  Expression of xenobiotic-metabolizing cytochrome P450 forms in human full-term placenta. , 1996, Biochemical pharmacology.

[35]  P. Royall,et al.  The relevance of the amorphous state to pharmaceutical dosage forms: glassy drugs and freeze dried systems. , 1999, International journal of pharmaceutics.

[36]  A. Peregrina,et al.  The influence of coffee with milk and tea with milk on the bioavailability of tetracycline. , 1997, Biopharmaceutics & drug disposition.

[37]  B. Springthorpe,et al.  Which Hydroxy? Evidence for Species Differences in the Regioselectivity of Glucuronidation in Rat, Dog, and Human in Vitro Systems and Dog in Vivo , 2006, Drug Metabolism and Disposition.

[38]  S. Imaoka,et al.  A sex-specific form of cytochrome P-450 catalyzing propoxycoumarin O-depropylation and its identity with testosterone 6 beta-hydroxylase in untreated rat livers: reconstitution of the activity with microsomal lipids. , 1988, Journal of biochemistry.

[39]  W. Tong,et al.  Impact of solid state properties on developability assessment of drug candidates. , 2004, Advanced drug delivery reviews.

[40]  W. Hauck,et al.  Interpatient variability in bioavailability is related to the extent of absorption: Implications for bioavailability and bioequivalence studies , 1996, Clinical pharmacology and therapeutics.

[41]  L. Benet,et al.  Functional characterization of monocarboxylic acid, large neutral amino acid, bile acid and peptide transporters, and P-glycoprotein in MDCK and Caco-2 cells. , 2002, Journal of pharmaceutical sciences.

[42]  Ferenc Darvas,et al.  In Silico and Ex silico ADME approaches for drug discovery. , 2002, Current topics in medicinal chemistry.

[43]  S. Pond,et al.  First-Pass Elimination Basic Concepts and Clinical Consequences , 1984, Clinical pharmacokinetics.

[44]  G. Amidon,et al.  Applying the biopharmaceutics classification system to veterinary pharmaceutical products. Part II. Physiological considerations. , 2002, Advanced drug delivery reviews.

[45]  G. Edwards,et al.  Animal models for the study of intestinal lymphatic drug transport. , 2001, Advanced drug delivery reviews.

[46]  R. Austin,et al.  A UNIFIED MODEL FOR PREDICTING HUMAN HEPATIC, METABOLIC CLEARANCE FROM IN VITRO INTRINSIC CLEARANCE DATA IN HEPATOCYTES AND MICROSOMES , 2005, Drug Metabolism and Disposition.

[47]  G. Farrell,et al.  Sexually dimorphic expression of rat CYP3A9 and CYP3A18 genes is regulated by growth hormone. , 1998, Biochemical and biophysical research communications.

[48]  D. Shen,et al.  Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. , 1997, The Journal of pharmacology and experimental therapeutics.

[49]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[50]  K. Luthman,et al.  Correlation of drug absorption with molecular surface properties. , 1996, Journal of pharmaceutical sciences.

[51]  W. Curatolo,et al.  Drug polymorphism and dosage form design: a practical perspective. , 2004, Advanced drug delivery reviews.

[52]  J. Lin,et al.  Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[53]  P. Pfeiffer,et al.  Patient preference for oral or intravenous chemotherapy: a randomised cross-over trial comparing capecitabine and Nordic fluorouracil/leucovorin in patients with colorectal cancer. , 2006, European journal of cancer.

[54]  A. P. Lötter,et al.  Kinetic study of the solid-state photolytic degradation of two polymorphic forms of furosemide , 1992 .

[55]  Panos Macheras,et al.  In silico prediction of ADME and pharmacokinetics. Report of an expert meeting organised by COST B15. , 2002, European Journal of Pharmaceutical Sciences.

[56]  J. Castle,et al.  Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: A resource for investigations into drug disposition , 2006, Xenobiotica; the fate of foreign compounds in biological systems.

[57]  J. Gustafsson,et al.  Gender differences in rat hepatic CYP2C gene expression--regulation by growth hormone. , 1998, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[58]  R. Fontana,et al.  Effects of a chargrilled meat diet on expression of CYP3A, CYP1A, and P-glycoprotein levels in healthy volunteers. , 1999, Gastroenterology.

[59]  S. Imaoka,et al.  Catalytic specificity of CYP2D isoforms in rat and human. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[60]  Colin W Pouton,et al.  Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[61]  G. Kirchner,et al.  Intestinal metabolism of cyclosporine A in human heart transplant recipients. , 1998, Transplantation proceedings.

[62]  Abu T M Serajuddin,et al.  IV-IVC considerations in the development of immediate-release oral dosage form. , 2005, Journal of pharmaceutical sciences.

[63]  C. Klaassen,et al.  Tissue mRNA expression of the rat UDP-glucuronosyltransferase gene family. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[64]  A. Boobis,et al.  Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. , 1990, British journal of clinical pharmacology.

[65]  W. L. Chiou Effect of ‘unstirred’ water layer in the intestine on the rate and extent of absorption after oral administration , 1994, Biopharmaceutics & drug disposition.

[66]  L. Marnett,et al.  Roles of individual human cytochrome P-450 enzymes in the bioactivation of benzo(a)pyrene, 7,8-dihydroxy-7,8-dihydrobenzo(a)pyrene, and other dihydrodiol derivatives of polycyclic aromatic hydrocarbons. , 1989, Cancer research.

[67]  J. Hakkola,et al.  Detection of cytochrome P450 gene expression in human placenta in first trimester of pregnancy. , 1996, Biochemical pharmacology.

[68]  Baggot Jd Clinical pharmacokinetics in veterinary medicine. , 1992 .

[69]  D. Shen,et al.  First‐pass metabolism of midazolam by the human intestine , 1996, Clinical pharmacology and therapeutics.

[70]  S. S. Davis,et al.  Lipid vehicles for intestinal lymphatic drug absorption , 1987, The Journal of pharmacy and pharmacology.

[71]  J. Halpert,et al.  cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. , 2001, Molecular pharmacology.

[72]  W. Charman,et al.  The Mucosa of the Small Intestine , 2002, Clinical pharmacokinetics.

[73]  G. Frenning,et al.  Drug release modeled by dissolution, diffusion, and immobilization. , 2003, International journal of pharmaceutics.

[74]  G. Drusano,et al.  Sex differences in CYP3A activity using intravenous and oral midazolam , 2006, Clinical pharmacology and therapeutics.

[75]  A. Braune,et al.  Transformation of flavonoids by intestinal microorganisms. , 2003, International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition.

[76]  Alex Avdeef,et al.  Physicochemical Profiling (Solubility, Permeability and Charge State) , 2001 .

[77]  G. B. Smith,et al.  Human lung microsomal cytochrome P4501A1 (CYP1A1) activities: impact of smoking status and CYP1A1, aryl hydrocarbon receptor, and glutathione S-transferase M1 genetic polymorphisms. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[78]  Kristina Luthman,et al.  Polar Molecular Surface Properties Predict the Intestinal Absorption of Drugs in Humans , 1997, Pharmaceutical Research.

[79]  Gordon L Amidon,et al.  A Mechanistic Approach to Understanding the Factors Affecting Drug Absorption: A Review of Fundamentals , 2002, Journal of clinical pharmacology.

[80]  Hans Lennernäs,et al.  Does Fluid Flow Across the Intestinal Mucosa Affect Quantitative Oral Drug Absorption? Is It Time for a Reevaluation? , 1995, Pharmaceutical Research.

[81]  A. Lichtenstein Intestinal cholesterol metabolism. , 1990, Annals of medicine.

[82]  G. Corazza,et al.  Measurements of the jejunal unstirred layer in normal subjects and patients with celiac disease. , 1996, The American journal of physiology.

[83]  N. Benowitz,et al.  Clinical Pharmacokinetics of Lignocaine , 1978, Clinical pharmacokinetics.

[84]  P. Toutain,et al.  Bioavailability and its assessment. , 2004, Journal of veterinary pharmacology and therapeutics.

[85]  Narayanan Surendran,et al.  Improved intestinal transport of PD 158473, an N-methyl-D-aspartate (NMDA) antagonist, by involvement of multiple transporters. , 2002, Journal of pharmaceutical sciences.

[86]  D. Greenblatt,et al.  In vitro biotransformation of sildenafil (Viagra) in the male rat: the role of CYP2C11. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[87]  M Rowland,et al.  Species differences in size discrimination in the paracellular pathway reflected by oral bioavailability of poly(ethylene glycol) and D-peptides. , 1998, Journal of pharmaceutical sciences.

[88]  K. Inui,et al.  Intestinal absorption of drugs mediated by drug transporters: mechanisms and regulation. , 2003, Drug metabolism and pharmacokinetics.

[89]  B. Testa,et al.  Physicochemical profiling in drug research: a brief survey of the state-of-the-art of experimental techniques , 2002, Cellular and Molecular Life Sciences CMLS.

[90]  P. Artursson,et al.  Paracellular drug transport across intestinal epithelia: influence of charge and induced water flux. , 1999, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[91]  H. Lennernäs,et al.  Regional Gastrointestinal Absorption of the Beta-Blocker Pafenolol in the Rat and Intestinal Transit Rate Determined by Movement of 14C-Polyethylene Glycol (PEG) 4000 , 2004, Pharmaceutical Research.

[92]  J. Schellens,et al.  The Oral Route for the Administration of Cytotoxic Drugs: Strategies to Increase the Efficiency and Consistency of Drug Delivery , 2000, Investigational New Drugs.

[93]  Donald C. Monkhouse,et al.  Review ArticlePharmaceutical Salts , 1977 .

[94]  H. Adlercreutz,et al.  Metabolism of isoflavones and lignans by the gut microflora: a study in germ-free and human flora associated rats. , 2003, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[95]  S K Balani,et al.  Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[96]  J. Goldstein,et al.  Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. , 2001, Pharmacogenetics.

[97]  M. Stromberg,et al.  Anatomy and embryology of the laboratory rat , 1986 .

[98]  R. Obach,et al.  Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[99]  R. de Kanter,et al.  Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction , 2006, Expert opinion on drug metabolism & toxicology.

[100]  P. van Bladeren,et al.  Regioselectivity of phase II metabolism of luteolin and quercetin by UDP-glucuronosyl transferases. , 2002, Chemical research in toxicology.

[101]  D. Smith,et al.  Species differences in metabolism and pharmacokinetics: are we close to an understanding? , 1991, Drug metabolism reviews.

[102]  E. Hodgson,et al.  Metabolism of Endosulfan-α by Human Liver Microsomes and Its Utility as a Simultaneous in Vitro Probe for CYP2B6 and CYP3A4 , 2006, Drug Metabolism and Disposition.

[103]  R. Riley,et al.  Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[104]  A. Boobis,et al.  Expression and inducibility of P450 enzymes during liver ontogeny , 1997, Microscopy research and technique.

[105]  P. Rolan,et al.  Simultaneous investigation of indinavir nonlinear pharmacokinetics and bioavailability in healthy volunteers using stable isotope labeling technique: study design and model-independent data analysis. , 1999, Journal of pharmaceutical sciences.

[106]  Lipophilicity and biological acitivity. Drug transport and drug distribution in model systems and in biological systems. , 1979, Arzneimittel-Forschung.

[107]  Jaran Eriksen,et al.  CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population , 2006, Pharmacogenetics and genomics.

[108]  John-Michael Sauer,et al.  Clinical Pharmacokinetics of Atomoxetine , 2005, Clinical pharmacokinetics.

[109]  S. Sabnis Factors Influencing the Bioavailability of Peroral Formulations of Drugs for Dogs , 1999, Veterinary Research Communications.

[110]  F. Guengerich Comparisons of catalytic selectivity of cytochrome P450 subfamily enzymes from different species. , 1997, Chemico-biological interactions.

[111]  C. Porter,et al.  Bile Increases Intestinal Lymphatic Drug Transport in the Fasted Rat , 2005, Pharmaceutical Research.

[112]  Kazutaka Higaki,et al.  Gastrointestinal transit and drug absorption. , 2000, Biological & pharmaceutical bulletin.

[113]  Z T Chowhan,et al.  pH-solubility profiles or organic carboxylic acids and their salts. , 1978, Journal of pharmaceutical sciences.

[114]  G. Mckay,et al.  Quinidine but not quinine inhibits in man the oxidative metabolic routes of methoxyphenamine which involve debrisoquine 4-hydroxylase , 2004, European Journal of Clinical Pharmacology.

[115]  H. van de Waterbeemd,et al.  Property-based design: optimization of drug absorption and pharmacokinetics. , 2001, Journal of medicinal chemistry.

[116]  H. Yamazaki,et al.  Characterization of microsomal cytochrome P450 enzymes involved in the oxidation of xenobiotic chemicals in human fetal liver and adult lungs. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[117]  Aditya Mohan Kaushal,et al.  Amorphous drug delivery systems: molecular aspects, design, and performance. , 2004, Critical reviews in therapeutic drug carrier systems.

[118]  E NELSON,et al.  Solution rate of theophylline salts and effects from oral administration. , 1957, Journal of the American Pharmaceutical Association. American Pharmaceutical Association.

[119]  D. Bailey,et al.  Grapefruit juice—felodipine interaction: Effect of naringin and 6′,7′‐dihydroxybergamottin in humans , 1998, Clinical pharmacology and therapeutics.

[120]  John-Michael Sauer,et al.  Disposition and metabolic fate of atomoxetine hydrochloride: pharmacokinetics, metabolism, and excretion in the Fischer 344 rat and beagle dog. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[121]  R. Gugler,et al.  Effects of Antacids on the Clinical Pharmacokinetics of Drugs , 1990, Clinical pharmacokinetics.

[122]  K. Morris,et al.  Reactivity differences of indomethacin solid forms with ammonia gas. , 2002, Journal of the American Chemical Society.

[123]  G. Macfarlane,et al.  Collaborative JPEN‐Clinical Nutrition Scientific Publications Role of intestinal bacteria in nutrient metabolism , 1997 .

[124]  R. Kim,et al.  Intestinal Drug Transporter Expression and the Impact of Grapefruit Juice in Humans , 2007, Clinical pharmacology and therapeutics.

[125]  G. Flynn,et al.  Solubility of organic hydrochlorides. , 1972, Journal of pharmaceutical sciences.

[126]  J. DeSesso,et al.  Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats. , 2001, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[127]  J. Dressman,et al.  Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. , 1997, Advanced drug delivery reviews.

[128]  D. A. Smith,et al.  Potential role for P-glycoprotein in the nonproportional pharmacokinetics of UK-343,664 in man , 2001, Xenobiotica; the fate of foreign compounds in biological systems.

[129]  David R. Friend,et al.  Drug delivery to the small intestine , 2004, Current gastroenterology reports.

[130]  D. Smith,et al.  Human cytochrome P450s: selectivity and measurement in vivo. , 1998, Xenobiotica; the fate of foreign compounds in biological systems.

[131]  E. De Clercq,et al.  Species-dependent and site-specific intestinal metabolism of ester prodrugs. , 2000, International journal of pharmaceutics.

[132]  Ho-Chul Shin,et al.  Why is it Challenging to Predict Intestinal Drug Absorption and Oral Bioavailability in Human Using Rat Model , 2006, Pharmaceutical Research.

[133]  H. Pols,et al.  A common polymorphism in the CYP3A7 gene is associated with a nearly 50% reduction in serum dehydroepiandrosterone sulfate levels. , 2005, The Journal of clinical endocrinology and metabolism.

[134]  Ann Daly,et al.  Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression , 2001, Nature Genetics.

[135]  J. Lin,et al.  Species similarities and differences in pharmacokinetics. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[136]  Christoph Hiemke,et al.  Identification of P‐glycoprotein substrates and inhibitors among psychoactive compounds — implications for pharmacokinetics of selected substrates , 2004, The Journal of pharmacy and pharmacology.

[137]  K. Midha,et al.  Quinine is a more potent inhibitor than quinidine in rat of the oxidative metabolic routes of methoxyphenamine which involve debrisoquine 4-hydroxylase. , 1991, Xenobiotica; the fate of foreign compounds in biological systems.

[138]  R. Riley,et al.  The Development of a Cocktail CYP2B6, CYP2C8, and CYP3A5 Inhibition Assay and a Preliminary Assessment of Utility in a Drug Discovery Setting , 2007, Drug Metabolism and Disposition.

[139]  Vijay K Gombar,et al.  Role of ADME characteristics in drug discovery and their in silico evaluation: in silico screening of chemicals for their metabolic stability. , 2003, Current topics in medicinal chemistry.

[140]  P. Sinko,et al.  Intestinal drug transporters: in vivo function and clinical importance. , 2004, Current drug metabolism.

[141]  E. Nelson Comparative dissolution rates of weak acids and their sodium salts. , 2006, Journal of the American Pharmaceutical Association. American Pharmaceutical Association.

[142]  D W Nebert,et al.  The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. , 1997, Pharmacogenetics.

[143]  Han van de Waterbeemd,et al.  Pharmacokinetics and Metabolism in Drug Design: SMITH: PHARMACOKINETICS AND METABOLISM IN DRUG DESIGN O-BK , 2006 .

[144]  R. Eyjólfsson Enalapril maleate polymorphs: instability of form II in a tablet formulation. , 2002, Die Pharmazie.

[145]  Abu T M Serajuddin,et al.  Trends in solubility of polymorphs. , 2005, Journal of pharmaceutical sciences.

[146]  Karluss Thomas,et al.  Research strategies for safety evaluation of nanomaterials, part V: role of dissolution in biological fate and effects of nanoscale particles. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.

[147]  C. Nyström,et al.  Coulter Counter measurements of solubility and dissolution rate of sparingly soluble compounds using micellar solutions * , 1986, The Journal of pharmacy and pharmacology.

[148]  Han van de Waterbeemd,et al.  High-throughput and in silico techniques in drug metabolism and pharmacokinetics. , 2002 .

[149]  D W Nebert,et al.  P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. , 1996, Pharmacogenetics.

[150]  K. Reuhl,et al.  Constitutive and inducible levels of CYP1A1 and CYP1A2 in rat cerebral cortex and cerebellum , 2003, Archives of Toxicology.

[151]  W. S. Snyder,et al.  Report of the task group on reference man , 1979, Annals of the ICRP.

[152]  D. Winne Unstirred layer thickness in perfused rat jejunum in vivo , 1976, Experientia.

[153]  U. Brinkmann,et al.  Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. , 2001, Pharmacogenetics.

[154]  R. Strickley Solubilizing Excipients in Oral and Injectable Formulations , 2004, Pharmaceutical Research.

[155]  W. Peters,et al.  Cytochromes P-450 in the intestinal mucosa of man. , 1989, Biochemical pharmacology.

[156]  Oleg A Raevsky,et al.  Physicochemical descriptors in property-based drug design. , 2004, Mini reviews in medicinal chemistry.

[157]  T. Cresteil,et al.  Developmental expression of CYP2C and CYP2C-dependent activities in the human liver: in-vivo/in-vitro correlation and inducibility. , 1997, Pharmacogenetics.

[158]  W. L. Chiou,et al.  Similarity in the linear and non-linear oral absorption of drugs between human and rat. , 2000, International journal of clinical pharmacology and therapeutics.

[159]  Honghui Zhou Pharmacokinetic Strategies in Deciphering Atypical Drug Absorption Profiles , 2003, Journal of clinical pharmacology.

[160]  J. Dressman,et al.  Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. , 1997, Journal of pharmaceutical sciences.

[161]  P. Enck,et al.  Stress effects on gastrointestinal transit in the rat. , 1989, Gut.

[162]  Kjell Johnson,et al.  Integrated oral bioavailability projection using in vitro screening data as a selection tool in drug discovery. , 2004, International journal of pharmaceutics.

[163]  C. Lipinski Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.

[164]  P. Thomas,et al.  Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[165]  D. Nebert,et al.  Human CYP1A2: sequence, gene structure, comparison with the mouse and rat orthologous gene, and differences in liver 1A2 mRNA expression. , 1989, Molecular endocrinology.

[166]  K. Uekama,et al.  Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. , 1997, Journal of pharmaceutical sciences.

[167]  S. Krämer,et al.  Physicochemical properties in pharmacokinetic lead optimization. , 2001, Farmaco.

[168]  W. Jaeger,et al.  Clinical importance of hepatic cytochrome P450 in drug metabolism. , 1995, Drug metabolism reviews.

[169]  Shobha Bhattachar,et al.  The road map to oral bioavailability: an industrial perspective , 2006, Expert opinion on drug metabolism & toxicology.

[170]  G. Gregoriadis,et al.  Fat soluble vitamins in liposomes: studies on incorporation efficiency and bile salt induced vesicle disintegration. , 1993, Journal of drug targeting.

[171]  P. Enck,et al.  Repeated noninvasive measurement of gastrointestinal transit in rats , 1989, Physiology & Behavior.